UK markets closed
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • FTSE 250

    22,883.39
    +206.11 (+0.91%)
     
  • AIM

    1,232.54
    +4.45 (+0.36%)
     
  • GBP/EUR

    1.1675
    -0.0013 (-0.11%)
     
  • GBP/USD

    1.3754
    -0.0013 (-0.10%)
     
  • BTC-GBP

    25,094.40
    +331.57 (+1.34%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • DOW

    35,061.55
    +238.20 (+0.68%)
     
  • CRUDE OIL

    72.17
    +0.26 (+0.36%)
     
  • GOLD FUTURES

    1,802.10
    -3.30 (-0.18%)
     
  • NIKKEI 225

    27,548.00
    +159.80 (+0.58%)
     
  • HANG SENG

    27,321.98
    -401.86 (-1.45%)
     
  • DAX

    15,669.29
    +154.75 (+1.00%)
     
  • CAC 40

    6,568.82
    +87.23 (+1.35%)
     

Worldwide Artificial Pancreas Device Systems Industry to 2026 - Key Players Include Beta Bionics, Dexcom and Insulet Among Others

·7-min read

Dublin, July 16, 2021 (GLOBE NEWSWIRE) -- The "Artificial Pancreas Device Systems (APDS) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

The global artificial pancreas device systems (APDS) market exhibited strong growth during 2015-2020. Looking forward, the publisher expects the market to grow at a CAGR of 13.1% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

APDS refers to a closed-loop or automated insulin delivery system that manages blood glucose levels by regulating the production of insulin. It consists of a continuous glucose monitor (CGM), a subcutaneous insulin infusion pump and a controller that links the monitor with the pump. It runs a complex algorithm that determines the adequate levels of insulin and time of delivery based on the evaluation of real-time glucose readings. It is primarily used to minimize the risks of extreme fluctuations of glucose levels in the body.

The increasing prevalence of pancreatic cancer, pancreatitis and other chronic ailments is one of the key factors driving the growth of the market. Furthermore, the growing occurrence of diabetes and obesity, due to age-related factors, physical inactivity and unhealthy dietary patterns, is also contributing to the widespread adoption of APDS across the globe. The rising demand for efficient diabetes monitoring and minimally invasive (MI) drug delivery systems is also providing a boost to the market growth. APDS automatically monitors the glucose levels and administers doses of insulin throughout the day in controlled amounts. Various technological innovations, including the development of software-based wireless systems that are integrated with automated controls, are further contributing to the market growth. Moreover, regulatory bodies and governments of various nations are significantly investing in research and development (R&D) for the improvement of healthcare infrastructure across the globe. For instance, the Food and Drug Association (US FDA) in the United States is approving an increasing number of new and innovative products, which is creating a positive outlook for the market in the country.

Breakup by Device Type:

  • Threshold Suspend Device Systems

  • Control-to-Range Systems

  • Control-to-Target Systems

Breakup by Treatment Type:

  • Bi-hormonal

  • Insulin Only

  • Hybrid

Breakup by End-User:

  • Hospitals

  • Medical Centres

  • Others

Breakup by Region:

  • North America

  • United States

  • Canada

  • Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Indonesia

  • Europe

  • Germany

  • France

  • United Kingdom

  • Italy

  • Spain

  • Russia

  • Latin America

  • Brazil

  • Mexico

  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Beta Bionics Inc., Bigfoot Biomedical Inc., Dexcom Inc., Inreda Diabetic B.V., Insulet Corporation, Johnson & Johnson, Medtronic Inc., Roche Holding AG, Tandem Diabetes Care Inc., etc.

Key Questions Answered in This Report:

  • How has the global artificial pancreas device systems market performed so far and how will it perform in the coming years?

  • What are the key regional markets?

  • What has been the impact of COVID-19 on the global artificial pancreas device systems market?

  • What is the breakup of the market based on the device type?

  • What is the breakup of the market based on the treatment type?

  • What is the breakup of the market based on the end-user?

  • What are the various stages in the value chain of the industry?

  • What are the key driving factors and challenges in the industry?

  • What is the structure of the global artificial pancreas device systems market and who are the key players?

  • What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Artificial Pancreas Device Systems Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Device Type
6.1 Threshold Suspend Device Systems
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Control- to-Range Systems
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Control-to-Target Systems
6.3.1 Market Trends
6.3.2 Market Forecast

7 Market Breakup by Treatment Type
7.1 Bi-hormonal
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Insulin Only
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Hybrid
7.3.1 Market Trends
7.3.2 Market Forecast

8 Market Breakup by End-User
8.1 Hospital
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Medical Centres
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast

9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Indicators

14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Beta Bionics Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.2 Bigfoot Biomedical Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 Dexcom Inc.
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Inreda Diabetic B.V.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.5 Insulet Corporation
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Johnson & Johnson
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Medtronic Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.8 Roche Holding AG
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.9 Tandem Diabetes Care Inc.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials

For more information about this report visit https://www.researchandmarkets.com/r/2nbwns

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting